HOLON, Israel, Sept. 9,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that Dr. Roy
Granit, Head of Computational Discovery at Compugen will
present a poster on applying AI to gain insights into the novel
immune checkpoint PVRIG through single-cell and spatial
transcriptomics at the Single Cell Genomics 2024 conference
taking place between September 16-18,
2024, Corinthia, Greece.
Additional biological insights characterizing the uniqueness of
the novel immune checkpoint PVRIG discovered by Compugen, were
generated using Compugen's AI/ML-powered computational discovery
platform, recently branded as UnigenTM. The data further
support previous findings that PVRIG inhibition may be
differentiated from other immune checkpoints and may have the
potential to induce anti-tumor activity in indications previously
refractory to immunotherapy.
Poster presentation details:
Poster title:
Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG
Through Single-Cell and Spatial Transcriptomics
Poster number: 40
Presenter: Roy Granit, Ph.D.,
Head of Computational Discovery, Compugen Ltd.
Date: Monday, September 16,
2024
The poster will be available on the publications section of
Compugen's website, www.cgen.com, following presentation.
About Unigen™
Compugen has been at the forefront of
decoding cancer biology, with its AI/ML powered predictive
computational discovery platform, recently branded as Unigen™.
Unigen™ is Compugen's code-to-cure, flexible-loop platform for the
computational prediction of novel drug target discovery and
development of cancer immunotherapy. Unigen™ combines Compugen's
deep scientific knowledge, AI/ML predictive algorithms and a
cloud-based, technology-agnostic platform integrating a variety of
biological data such as multi-omics, single-cell RNA sequencing and
spatial omics data. The outcomes from Compugen's preclinical and
clinical trials enrich the proprietary knowledgebase to discover
additional novel drug targets and further understand complex
biology. To date, Unigen™ has yielded multiple novel
immuno-oncology drug targets, potential first- or best-in-class
clinical stage immuno-oncology programs, validating partnerships
with multiple pharmaceutical companies and undisclosed programs in
its early-stage pipeline.
About Compugen
Compugen is a clinical-stage
therapeutic discovery and development company utilizing its broadly
applicable predictive computational discovery platform
(UnigenTM) to identify new drug targets and biological
pathways for developing cancer immunotherapies. Compugen has
two proprietary product candidates in Phase 1 development: COM701,
a potential first-in-class anti-PVRIG antibody and COM902, a
potential best-in-class antibody targeting TIGIT for the treatment
of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody
where the TIGIT component is derived from Compugen's clinical stage
anti-TIGIT antibody, COM902, is in Phase 3 development by
AstraZeneca through a license agreement for the development of
bispecific and multispecific antibodies. In addition, the
Company's therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms
of immune resistance, of which the most advanced program, COM503, a
potential first-in-class, high affinity anti-IL-18 binding protein
antibody, which has been granted IND clearance from the FDA, is
licensed to Gilead. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-at-single-cell-genomics-2024-conference-302241834.html
SOURCE Compugen Ltd.